メタボリックシンドロームの概念のいわば前身で、上半身肥満、糖代謝異常（糖尿病）、高中性脂肪血症（高脂血症）、高血圧が合併した状態をさします。1989年にアメリカの研究者カプラン（Kaplan NM）によって提唱され、冠動脈疾患による死亡率が高く、まさに死の序曲を奏でるという意味合いから「死の四重奏（The Deadly Quartet）」と呼ばれました。
メタボリックシンドロームの概念との違いが曖昧に紹介されることがよくありますが、メタボリックシンドロームでは糖代謝異常、脂質代謝異常、高血圧の上流に、それらの原因として内臓脂肪蓄積を置いている点が大きく異なります。
メタボリックシンドロームは、この死の四重奏をはじめ、シンドロームX、インスリン抵抗性症候群、マルチプルリスクファクター症候群などの一連の概念を最終的に整理したものといえます。尚、特定健診・特定保健指導では、メタボリックシンドロームの和名表記の同義語として「内臓脂肪症候群」の呼称を用いています。
メタボリック‐シンドローム【metabolic syndrome】
死の四重奏
読み方：しのよんじゅうそう
別名：インスリン抵抗性症候群,マルチプルリスクファクター症候群,内臓脂肪症候群,危険因子集積症候群,メタボリックシンドローム
【英】：シンドロームX
別名：インスリン抵抗性症候群,マルチプルリスクファクター症候群,内臓脂肪症候群,危険因子集積症候群,メタボリックシンドローム
【英】：シンドロームX
メタボリックシンドローム
メタボリックシンドロームとは、肥満に伴って、内臓脂肪が蓄積し、内臓脂肪の働きにより病的な異常がもたらされる結果、軽度の糖代謝、脂質代謝の異常、あるいは血圧の上昇が起こり、個々の病態は軽度でもこれらの病態が重なり合って動脈硬化による心血管病のリスクが高まっている病態を言います。動脈硬化症や心血管病は生命に関わる病態であり、治療後の生活にも大きな支障を与える可能性があることから、その予防は重要となります。 メタボリックシンドロームは内臓脂肪蓄積を背景に糖代謝異常（空腹時血糖値110mg/dl以上）、脂質代謝異常（中性脂肪150mg/dl以上またはHDL40mg/ml未満）、高血圧（最大130mmHg以上または最小85mmHg以上）のうち２つ以上があてはまる場合に診断されます。しかし、適正な摂取エネルギー量を知り、過食を避け、適度な運動を継続することで予防が可能と考えられています。
メタボリックシンドローム【めたぼりっくしんどろーむ】
メタボリックシンドローム
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2023/07/22 07:46 UTC 版)
メタボリックシンドローム（英: Metabolic syndrome）とは、内臓脂肪型肥満（内臓肥満・腹部肥満）に高血糖・高血圧・脂質異常症のうち2つ以上の症状が一度に出ている状態をいう。日本語に訳すと代謝症候群という。単にメタボとも言われる。
- ^ a b c d 坂本穆彦 監修『標準病理学 第5版』、医学書院、2015年3月15日 第5版 第1刷 発行、P201
- ^ 岩波明『精神科医が狂気をつくる 臨床現現場からの緊急警告』、新潮社、2011年6月15日発行、158ページ
- ^ 滋賀医科大 上島弘嗣教授『日米共同調査』
- ^ “カロリーとは”. 株式会社タニタ. 2023年7月22日閲覧。
- ^ a b Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
- ^ a b DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
- ^ a b Kaplan NM. The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-1520.
- ^ Lemieux I, Pascot A, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small dense LDL) in men? Circulation 2000; 102: 179-184.
- ^ Ridker PM, Wilson PW, et al. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-2825.
- ^ Dandona P, Aljada A, et al. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111: 1448-1454.
- ^ Iso H, Kobayashi M, et al. Intake of fish and n-3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-based (JPHC) Study Cohort 1. Circulation 2006; 113: 195-202.
- ^ Ouellet V, Marois J, et al. Dietary cod protein improves insulin sensitivity in insulin-resistant men and women. Diabetes Care 2007; 30: 2816-2821.
- ^ a b Riserus U, Arnlov J, et al. Long-term predictors of insuli resistance. Role of lifestyle and metabolic factors in middle-aged men. Diabetes Care 2007; 30: 2928-2933.
- ^ Oh SW, Yoon YS, et al. Association between cigarette smoking and metabolic syndrome: the Korea National Health and Nutrition Examination Survey. Diabetes Care 2005; 28: 2064–2066.
- ^ Gustat J, Srinivasan SR, et al. Relation of self-rated measures of physical activity to multiple risk factors of insulin resistance syndrome in young adults: the Bogalusa Heart Study. J Clin Epidemiol 2002; 55: 997-1006.
- ^ Ford ES, Giles WH, et al. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
- ^ Apridonidze T, Essah PA, et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 90: 1929-1935.
- ^ Ruderman NB, Schneider SH, et al. The “metabolically-obese,” normal-weight individual. Am J Clin Nutr 1981; 34: 1617-1621.
- ^ Nakamura T, Tokunaga K, et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Athyerosclerosis 1997; 107: 239-246.
- ^ Lamarche B, Tchernof A, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955-1961.
- ^ World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO Consultation. Geneva, World Health Org, 1999.
- ^ Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabetes Med 1999; 16: 442-443.
- ^ Lemieux I, Pascot A, et al. Hypertriglyceridemic waist. A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000; 102: 179-184.
- ^ Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
- ^ Einhorn D, Reaven GM, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237-252.
- ^ Ridker PM, Wilson PWF, et al. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-2825.
- ^ Grundy SM, Cleeman JI, et al. Diagnosis and management of the metabolic syndrome: a statement for health care professionals: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
- ^ Kahn R, Buse J, et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304.
- ^ a b Grundy SM. Does the metabolic syndrome exist? Diabetes Care 2006; 29: 1689-1692.
- ^ Kahn R. The metabolic syndrome (emperor) wears no clothes. Diabetes Care 2006; 29: 1693-1696.
- ^ a b c Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 2006; 83: 1237-1247.
- ^ Grundy SM. Does a diagnosis of metabolic syndrome have value in clinical practice. Am J Clin Nutr 2006; 83: 1248-1251.
- ^ Ferrannini E. Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 2007; 92: 396-398.
- ^ Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007; 92: 399-404.
- ^ Kahn R. Metabolic syndrome. Is it a syndrome? Does it matter. Circulation 2007; 115: 1806-1811.
- ^ Beaser RS, Levy P. Metabolic syndrome. A work in progress, but a useful construct. Circulation 2007; 115: 1812-1818.
- ^ Sundstrom J, Vallhagen E, et al. Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care 2006; 29: 1673-1674.
- ^ Eckel RH, Kahn R, et al. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 2006; 113: 2943-2946.
- ^ Malik S, Wong ND, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250.
- ^ McNeil AM, Rosamond WD, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005; 28: 385-390.
- ^ Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care 2005; 28: 1769-1778.
- ^ Wilson PWF, D’Agostino RB, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
- ^ The DECODE Study Group, Qiao Q. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 2006; 49: 2837-2846.
- ^ Gami AS, Witt BJ, et al. Metabolic syndrome and risk of incident cardiovascular events and death. J Am Coll Cardiol 2007; 49: 403-414.
- ^ Ninomia T, Kubo M, et al. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population. The Hisayama Study. Stroke 2007; 38: 2063-2069.
- ^ Sone H, Tanaka S, et al. The new worldwide definition of metabolic syndrome is not a better diagnostic predictor of cardiovascular disease in Japanese diabetic patients than the existing definitions. Diabetes Care 2006; 29: 145-147.
- ^ Katzmarzyk PT, Janssen I, et al. The importance of waist circumference in the definition of metabolic syndrome. Prospective analyses of mortality in men. Diabetes Care 2006; 29: 404-409.
- ^ Chen H, Pan W. Probable blind spot in the International Diabetes Federation definition of metabolic syndrome. Obesity 2007; 15: 1096-1100.
- ^ Yoon YS, Lee ES, et al. The new definition of metabolic syndrome by the International Diabetes Federation is less likely to identify metabolically abnormal but non-obese individuals than the definition by the revised National Cholesterol Education Program: the Korea NHANES Study. Int J Obes 2007; 31: 528-534.
- ^ Tong PC, Kong AP, et al. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program’s Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1206-1211.
- ^ Tanomsup S, Aekplakorn W, et al. A comparison of components of two definitions of the metabolic syndrome related to cardiovascular disease and all-cause mortality in a cohort study in Thailand. Diabetes Care 2007; 30: 2138-2140.
- ^ Lorenzo C, Serrano-Rios M, et al. Is waist circumference an essential component of the metabolic syndrome? Diabetes Care 2007; 30: 2141-2142.
- ^ Klein S, Allison DB, et al. Waist circumference and cardiometabolic risk: a consensus statement from Shaping America’s Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care 2007; 30: 1647-1652.
- ^ The Examination Committee of Criteria for “Obesity Disease” in Japan, the Japanese Society for the Study of Obesity. New Criteria for “Obesity Disease” in Japan. Circ J 2002; 66: 987-992.
- ^ The Examination Committee of Criteria for Metabolic Syndrome. The definition and criteria of metabolic syndrome. J Jpn Soc Intern Med 2005; 94: 794-809, (in Japanese).
- ^ Matsuzawa YM. Pathophysiology and molecular mechanism of visceral fat syndrome: the Japanese experience. Diabetes/Metab Rev 1997; 13: 3-13.
- ^ Pou KM, Massaro JM, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress. The Framingham Heart Study. Circulation 2007; 116: 1234-1241.
- ^ Wellen KE, Fucho R, et al. Coordinated regulation of nutrient and inflammatory response by STAMP2 is essential for metabolic homeostasis. Cell 2007; 129: 537-548.
- ^ Oda E. New criteria for ‘obesity disease’ in Japan. Circ J 2006; 70: 150.
- ^ Oda E, Watanabe K. Japanese criteria of metabolic syndrome. Circ J 2006; 70: 364.
- ^ Oda E. Cut points of waist circumference. Diabetes Care 2006; 29: 1188-1189.
- ^ Hayashi T, Boyko E, et al. Minimum waist and visceral fat values for identifying Japanese Americans at risk for the metabolic syndrome. Diabetes Care 2007; 30: 120-127.
- ^ Tsubota N. Misuse of regression analysis and correlation in “New criteria for ‘obesity disease’ in Japan”. Circ J 2007; 71: 2001.
- ^ Hara K, Matsushita Y, et al. A proposal for the cutoff point of waist circumference for the diagnosis of metabolic syndrome in the Japanese population. Diabetes Care 2006; 29: 1123-1124.
- ^ Miyawaki T, Hirata M, et al. Prevalence of metabolic syndrome in Japan by MONKS (Metabolic Syndrome and Abdominal Obesity at NTT West Kyoto Study). Nippon Rinsho 2006; 64 (Suppl 9): s84-s87.
- ^ Oizumi T, Daimon M, et al. A proposal for the cutoff point of wait circumference for the diagnosis of metabolic syndrome in the Japanese population. Circ J 2006; 70: 1663.
- ^ Ohkubo T, Kikuya M, et al. A proposal for the cutoff point of wait circumference for the diagnosis of metabolic syndrome in the Japanese population. Diabetes Care 2006; 29: 1986-1987.
- ^ a b c Kiyohara Y, Doi Y, et al. Actual evidence of metabolic syndrome. J Jpn Soc Intern Med 2006; 95: 1710-1715, (in Japanese).
- ^ Kadota A, Hozawa A, et al. Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990-2000. Diabetes Care 2007; 30: 1533-1538.
- ^ Okamura T, Nakamura K, et al. Effect of combined cardiovascular risk factors on individual and population medical expenditures: A 10 year cohort study of National Health Insurance in a Japanese population. Circ J 2007; 71: 807-813.
- ^ Alverti KGMM, Zimmet P, et al. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
- ^ Oda E, Abe M, et al. Considerable disagreement among definitions of metabolic syndrome for Japanese. Circ J 2007; 71:1239-1243.
[続きの解説]
「メタボリックシンドローム」の続きの解説一覧
- 1 メタボリックシンドロームとは
- 2 メタボリックシンドロームの概要
- 3 診断基準
- 4 脚注
メタボリックシンドローム
「メタボリックシンドローム」の例文・使い方・用例・文例
- メタボリックシンドロームを防ぐ
- メタボリックシンドロームには腹部の肥満やインスリン抵抗性などいくつかの代謝に関わる危険因子の組み合わせが含まれる。
- メタボリックシンドロームになっている人々は動脈硬化，心(しん)筋(きん)梗(こう)塞(そく)，脳(のう)梗(こう)塞(そく)などの病気のリスクが高い。
- 政府の概算によると，40歳から74歳までの男性の25％，女性の10％がメタボリックシンドロームになっている。
- このようにして，メタボリックシンドロームにつながることの多い危険因子を回避できるかもしれない。
- 自転車はまた，メタボリックシンドロームを心配する人々の間でも人気を集めている。
- ２月に京都大学などの団体の研究者のグループが，トマトの中の物質がメタボリックシンドロームを防ぐのに役立つことを発見したと発表した。
Weblio日本語例文用例辞書はプログラムで機械的に例文を生成しているため、不適切な項目が含まれていることもあります。ご了承くださいませ。
固有名詞の分類
- メタボリックシンドﾛｰﾑのページへのリンク
